Results from the primary analysis of the ongoing phase 3 clinical trial of US biotechnology company Moderna's Covid-19 vaccine have revealed 94.1 per cent efficacy of the therapeutic in preventing symptomatic infections and severe illness, according to a peer-reviewed study.from World News Headlines, Latest International News, World Breaking News - Times of India https://ift.tt/3n334dk
Post a Comment